Search Results
Your search for ,had matches 18486 pages
Showing 7251 - 7300Novel Risk Calculator for Sentinel Node Positivity in Patients With Melanoma
As reported in the Journal of Clinical Oncology, Lo et al developed a novel risk calculator for sentinel node metastasis—the Melanoma Institute Australia Nomogram—that appears to more accurately predict risk of metastasis in patients with primary cutaneous melanoma than other commonly used risk...
Long-Term Outcomes With Pembrolizumab for Cisplatin-Ineligible Advanced Urothelial Cancer
As reported in the Journal of Clinical Oncology by Vuky et al, long-term follow-up in the phase II KEYNOTE-052 study has shown durable responses with first-line pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer, with higher response rates and longer survival in...
Addition of Rituximab to Standard Chemotherapy in Pediatric Patients With High-Risk, Mature B-Cell Non-Hodgkin Lymphoma
In a European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group phase III trial reported in The New England Journal of Medicine, Minard‑Colin et al found that the addition of rituximab to standard Lymphomes Malin B (also known as Lymphome Malin de Burkitt, or LMB) chemotherapy ...
Sedentary Behavior and Risk of Cancer Mortality
In a study that investigated objective measures of sedentary behavior and cancer mortality, researchers found that greater inactivity was independently associated with a higher risk of dying from cancer. An accelerometer was used to measure physical activity, rather than relying on participants to...
Long-Term Survival Outcomes With Different Durations of Adjuvant Imatinib for Gastrointestinal Stromal Tumors
In a 10-year follow-up of the phase III SSGXVIII/AIO trial reported in JAMA Oncology, Heikki Joensuu, MD, and colleagues found that 3 years vs 1 year of adjuvant treatment with imatinib was associated with superior overall survival among patients with high-risk gastrointestinal stromal tumors. The ...
Effect of Radiation Boost to Residual Disease in High-Risk Neuroblastoma
In an analysis from the Children’s Oncology Group (COG) ANBL0532 study reported in the Journal of Clinical Oncology, Liu et al found that a radiotherapy boost to the gross residual tumor in patients with high-risk neuroblastoma did not appear to improve outcomes compared with patients in another...
I’m Not Too Young for Colorectal Cancer
The first symptoms I had of colorectal cancer—blood in my stool and abdominal pain—coincided with surgery I had to remove my appendix in the spring of 2017. My surgeon attributed the symptoms to the appendectomy and to the medications I received both before and after the surgery. In addition to...
New Information From NCCN on Overcoming Challenges for People With Head and Neck Cancer
The National Comprehensive Cancer Network® (NCCN®) has now published a third book to complete the NCCN Guidelines for Patients®: Head and Neck Cancers series. Each book contains detailed, expert guidance on what to expect and management options for various cancers that impact the mouth and throat....
Melanoma Awareness: Outlook From a Young Adult
When I was 18, I was diagnosed with stage II melanoma. I had a strange spot on my back that I mentioned to my dermatologist, almost as an afterthought. It never occurred to me it could be skin cancer, let alone the most dangerous kind. I have fair skin but was by no means a sun worshipper. My...
Extended-Fraction Radiation Therapy for Bone Metastases Represents Low-Value Care but Continues to Be Widely Practiced
An analysis of radiation therapy patterns among more than 12,000 Medicare patients treated for bone metastases found that 23.4% received extended-fraction radiation therapy, “wasting both health-care dollars and precious patient time,” according to the investigators.1 One-third of the treating...
An Honored Poet Explores a Lust for Life on the Boundaries of Near Death
"When the technician leaves the room, I turn my head toward the screen to interpret neoplasms, the webs of nerves, the small lit fonts in which my pathology and/or future or future end might be written. The first tumor I ever saw was a darkness on that screen, round with a long craggy finger...
Capmatinib for Metastatic NSCLC With MET Exon 14 Skipping Mutation
On May 6, 2020, the oral mesenchymal-epithelial transition (MET) kinase inhibitor capmatinib was granted accelerated approval for the treatment of adult patients who have metastatic non–small cell lung cancer (NSCLC) with tumors that have a mutation that leads to MET exon 14 skipping, as detected...
AIDS Research Led to Appreciation of the Power of Plants and Integrative Medicine in Cancer Care for Donald I. Abrams, MD
The path that led Donald I. Abrams, MD, to a career in oncology was a circuitous one. Although his love of science began when he was a student at Cleveland Heights High School in Ohio, and continued during college at Brown University, where he received an AB in molecular biology in 1972, he was...
COVID-19 and Patients With Cancer: A Call to Action for Trainees
As oncology trainees, we develop skills to synthesize complex data and communicate this information with empathy as we accompany our patients through the trenches of a cancer diagnosis. With the current COVID-19 pandemic, an unprecedented layer of challenges has surfaced, as our patients who are...
Pigeon English
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of tolerating cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
Small Study Finds Olanzapine Reduces Nausea and Vomiting Caused by Advanced Cancer
The antipsychotic agent olanzapine may be helpful in reducing nausea and vomiting caused by advanced cancer, according to results of a study by Loprinzi et al published recently in JAMA Oncology. “There was a dramatic reduction [in nausea and vomiting] within 24 hours in the people who received...
Polio and Cancer Survivor Mickie McGraw Channels the Power of Creative Arts to Heal Broken Bodies and Minds
GUEST EDITOR Dr. Abraham is Professor of Medicine, Lerner College of Medicine, and Chair of the Hematology and Medical Oncology Department at Taussig Cancer Institute, Cleveland Clinic. In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with pioneering art ...
Study Confirms Effective, Less-Toxic Alternative to Standard Treatment of Adults With Burkitt Lymphoma
In a recent study reported in the Journal of Clinical Oncology,1 an alternative treatment regimen that is less toxic than standard dose-intensive chemotherapy was found to be highly effective for adults with Burkitt lymphoma across all age groups and independent of HIV status. In addition to being...
You-Can-Do-Anything Philosophy Early in Life Inspired Breast Surgeon Laura S. Dominici, MD
Breast surgical oncologist Laura S. Dominici, MD, was born and reared in Litchfield, a small town in the southern portion of New Hampshire. “Our house was on a long dirt road, in a very rural area,” she shared. “There were only about 5,000 residents in the town. My mother was a teacher, and my dad...
Woman With an Ovarian Tumor
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era: 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
Study Identifies Potential Approach to Treat Severe Respiratory Distress in Patients With COVID-19
Early data from a clinical study published in Science Immunology1 suggest that blocking the Bruton’s tyrosine kinase (BTK) protein provided clinical benefit to a small group of patients with severe COVID-19 infection.1 Roschewski et al observed that the off-label use of the BTK inhibitor...
Study Finds Alpelisib Effective After CDK4/6 Inhibition in Advanced Breast Cancer
The PIK3CA inhibitor alpelisib appears to be effective in patients with PIK3CA-positive, hormone receptor–positive/HER2-negative advanced breast cancer previously treated with a cyclin-dependent kinase (CDK) 4/6 inhibitor plus an aromatase inhibitor, according to the phase II BYLieve trial.1 More...
Survey Shows Young-Onset Colorectal Cancer May Be Overlooked in Exam Rooms
The Colorectal Cancer Alliance recently released findings from its latest survey of patients with young-onset colorectal cancer and survivors. The Never Too Young Survey shares the self-reported medical, psychosocial, and quality-of-life experiences of this often-overlooked population to better...
ASCO20 Virtual Scientific Program: Next-Generation Oncology Highlights
The ASCO20 Virtual Scientific Program was different in many ways, not only because of the virtual modality forced by the COVID-19 pandemic, but also because of the resilience of the scientific society and my colleagues around the world. I’m in the plenary session of the ASCO 2025 Annual Meeting....
American Association for Cancer Research Announces Distinguished Public Service Award Recipients
The American Association for Cancer Research (AACR) recently announced the presentation of Distinguished Public Service Awards to four individuals whose work has exemplified the AACR’s mission to prevent and cure all cancers through research, education, communication, collaboration, science policy, ...
Brigatinib for ALK-Positive Metastatic Non–Small Cell Lung Cancer
On May 22, 2020, brigatinib was approved for the treatment of adult patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC), as detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 The FDA also approved the Vysis ALK Break Apart FISH Probe Kit as a companion...
Blood Test Improves Screening for Hepatocellular Carcinoma
Researchers at the National Institutes of Health have developed a new test that may help identify individuals who may be likely to develop hepatocellular carcinoma. A study of the new approach was led by researchers at the National Cancer Institute (NCI). The findings were published in the journal...
Global Study Indicates Oncology Pharmacists Face Restricted Access to Essential PPE
Oncology pharmacy practitioners around the world are fighting to provide patients who have cancer with high-quality care despite increasingly limited and sometimes restricted personal protective equipment (PPE) as well as impaired access to essential anticancer medication, according to study...
ASCO Survey on Early Impact of COVID-19 on Performance of Oncology Clinical Trials
In an article published in JCO Oncology Practice, David Waterhouse, MD, MPH, of Oncology Hematology Care, Cincinnati, Ohio, and colleagues presented the results of a recent ASCO survey of clinical programs on the early impact of the COVID-19 pandemic on the performance of oncology clinical...
Ruxolitinib Improves Response Rates in Glucocorticoid-Refractory Acute Graft-vs-Host Disease After Allogeneic SCT
In the phase III REACH2 trial reported in TheNew England Journal of Medicine, Robert Zeiser, MD, of the Department of Hematology, Oncology, and Stem Cell Transplantation, University Medical Center Freiburg, Germany, and colleagues found that the JAK1/2 inhibitor ruxolitinib improved response rate...
Acalabrutinib With or Without Obinutuzumab vs Chlorambucil/Obinutuzumab in Previously Untreated CLL
As reported inThe Lancet by Jeff P. Sharman, MD, of Willamette Valley Cancer Institute/US Oncology, Eugene, Oregon, and colleagues, the phase III ELEVATE-TN trial has shown significantly improved progression-free survival with both acalabrutinib/obinutuzumab and acalabrutinib monotherapy vs...
Ramucirumab Plus Erlotinib in Treatment of EGFR-Mutant Metastatic NSCLC
On May 29, 2020, ramucirumab was approved for use in combination with erlotinib for first-line treatment of metastatic non–small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 (L858R) substitution mutation.1,2 Supporting Efficacy Data Approval was based on findings from the...
First-Line Atezolizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone in Advanced Urothelial Cancer
As reported in The Lancet by Matthew D. Galsky, MD, of Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, and colleagues, the phase III IMvigor130 trial has shown prolonged progression-free survival with first-line atezolizumab plus platinum-based chemotherapy vs...
Improving Care for Women With Late-Stage Breast Cancer
The global toll of breast cancer on women is staggering. In 2018, nearly two million new breast cancer cases were diagnosed, an increase of more than 20% since 2008,1 and mortality rates have increased by 14%, bringing the annual number of deaths worldwide from the cancer to more than 611,625.2...
Olaparib for Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
On May 19, 2020, olaparib was approved for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer who experienced disease progression after treatment with...
Ripretinib in Previously Treated Advanced Gastrointestinal Stromal Tumor
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 15, 2020, the receptor tyrosine kinase inhibitor...
Benefit Shown for AKT Inhibitor in LOTUS Survival Analysis
In the phase II LOTUS trial, the addition of the AKT inhibitor ipatasertib to paclitaxel in the first-line treatment of patients with advanced triple-negative breast cancer yielded a strong numerical improvement—a median gain of 9 months—in overall survival, in the final survival analysis reported...
Expert Point of View: Antonio Llombart-Cussac, MD, PhD
Discussant of the abstracts, Antonio Llombart-Cussac, MD, PhD, of Hospital Arnau de Vilanova, Universidad Catolica Valencia, Spain, noted that establishing these regimens in the third-line setting of metastatic disease and beyond will require demonstration of consistent gains in both...
Newer Late-Line Treatments May Change Front-Line Standard of Care in HER2-Positive Metastatic Breast Cancer
First- and second-line treatments of HER2-positive metastatic breast cancer have become the standard of care based on solid gains in overall survival, but the prevalence of resistance to these agents is increasing; up to 55% of patients will ultimately develop brain metastases. According to a pair...
ASCO20 Virtual Scientific Program Convened Record Number of Oncology Professionals From Across the Globe
ASCO announced record-breaking attendance at its 3-day ASCO20 Virtual Scientific Program, held online from May 29 through May 31. More than 42,700 attendees from 138 countries have participated thus far, learning virtually about new clinical cancer advances in every area of cancer research....
Repeat Breast Preservation: First Consideration in a Second Ipsilateral Breast Tumor Event
Worldwide, nearly 1.7 million women will be diagnosed with breast cancer. Of that number, nearly 300,000 Americans and more than 500,000 Europeans will be diagnosed with both invasive and in situ breast cancers.1,2 Breast-preserving surgery will initially be performed on approximately 60% of...
Expert Point of View: Taofeek Kunie Owonikoko, MD, PhD
Study discussant Taofeek Kunie Owonikoko, MD, PhD, Professor and Vice Chair of Hematology/Oncology, Winship Cancer Institute at Emory University, Atlanta, had praise for the design of KEYNOTE-604. He noted the adoption of the combination of pembrolizumab plus etoposide/platinum for the treatment of ...
First-Line Pembrolizumab Added to Standard Chemotherapy Improved Progression-Free Survival in Extensive-Stage Small Cell Lung Cancer
Pembrolizumab added to etoposide and platinum significantly improved progression-free survival compared with placebo and etoposide/platinum as first-line therapy in patients with newly diagnosed, extensive-stage small cell lung cancer (SCLC).1 These results from the randomized, double-blind, phase...
FDA Approves Pembrolizumab for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma
On June 24, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable with surgery or radiation. KEYNOTE-629 Efficacy was investigated in KEYNOTE-629, a multicenter, multicohort,...
Highlights From Complementary and Integrative Medicine Research and Implications for Clinical Practice
Due to COVID-19, this year’s ASCO Annual Meeting was convened using a virtual format. It was multidisciplinary, featuring more than 250 oral and 2,500 poster presentations from around the world in 24 disease-based and specialty tracks. Among the exciting talks in the session on symptoms and...
Results of a COVID-19 and Cancer Consortium (CCC19) Cohort Study
As reported in The Lancet by Kuderer et al, a cohort study using the COVID-19 and Cancer Consortium (CCC19) database has shown that increased risk of severe COVID-19 in patients with cancer is associated with such factors as age, comorbidities, performance status, hematologic malignancy, and...
Efficacy Outcomes With C-MTX in Newly Diagnosed Patients With Pediatric T-Cell Lymphoblastic Lymphoma
As reported in the Journal of Clinical Oncology by Hayashi et al, the Children’s Oncology Group AALL0434 study has shown “excellent” outcomes with Capizzi-based methotrexate/pegaspargase (C-MTX) treatment in patients with newly diagnosed pediatric T-cell lymphoblastic lymphoma (T-LL). The addition...
Trastuzumab Deruxtecan Shows Benefit in Refractory Colorectal Cancer
Having recently gained approval in metastatic breast cancer, fam-trastuzumab deruxtecan-nxki (T-DXd) is now proving its worth in metastatic colorectal cancer, according to results of the phase II DESTINY-CRC01 study in patients with HER2-positive disease.1 T-DXd is an antibody-drug conjugate...
Study Links Financial Hardship to More Emergency Room Visits, Less Preventive Care Among Cancer Survivors
A new study has found higher medical and nonmedical financial hardships are independently associated with more emergency department visits, lower receipt of some preventive services, and worse self-rated health in cancer survivors. The authors of the study warn that as health-care costs grow, unmet ...
Ivosidenib for IDH1-Mutant Advanced Glioma
In a phase I study reported in the Journal of Clinical Oncology, Mellinghoff et al found that ivosidenib was well tolerated in patients with IDH1-mutant advanced glioma and was associated with prolonged disease control in those with nonenhancing glioma. Study Details The study included 66 evaluable ...
